OptiBiotix Health Regulatory News (OPTI)

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Directorate change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that, further to the announcement on 23 October 2024, David Blain has been appointed to the Board as Finance Director and Company Secretary effective from 7 January 2025.

David is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

David's appointment to this part-time role will see him work closely with the OptiBiotix team to support the focus on driving each business unit and the Group to profitability.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of David Jonathan Blain (aged 63):

David Blain does not hold any ordinary shares, options or warrants over new ordinary shares in the Company.

There is no further information regarding David Blain required to be disclosed under the AIM Rules.

Stephen O'Hara, CEO of OptiBiotix commented: "We are pleased to confirm the appointment of David as Finance Director and Company Secretary. The appointment reflects the Board's focus on managing costs and building revenues to create profitable business units and an international business with well-known global brands."

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.